Patents by Inventor Roger D. Cone
Roger D. Cone has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10294214Abstract: Disclosed herein are positive allosteric modulators of melanocortin receptor and methods of using such modulators.Type: GrantFiled: June 7, 2017Date of Patent: May 21, 2019Assignees: Vanderbilt University, King's College London, Glaxo Group LimitedInventors: Roger D. Cone, Michael J. Bishop, Eugene L. Stewart, Lawrence A. Wolfe, Jaques Pantel, Julien Sebag, C. David Weaver, Savannah Williams, Helen Cox, Iain Tough, Luis Diaz Gimenez, Subramanian Baskaran
-
Publication number: 20170349571Abstract: Disclosed herein are positive allosteric modulators of melanocortin receptor and methods of using such modulators.Type: ApplicationFiled: June 7, 2017Publication date: December 7, 2017Inventors: Roger D. Cone, Michael J. Bishop, Eugene L. Stewart, Lawrence A. Wolfe, Jaques Pantel, Julien Sebag, C. David Weaver, Savannah Williams, Helen Cox, Ian Tough, Luis Diaz Gimenez, Subramanian Baskaran
-
Patent number: 9744171Abstract: Positive allosteric modulators of melanocortin receptors, especially allosteric potentiators of the receptors MC3R and MC4R are described herein. Also provided are pharmaceutical compositions containing the positive allosteric modulators and methods of treating obesity or an obesity-related disorder such as type 2 diabetes, comprising administering an effective amount of the positive allosteric modulator.Type: GrantFiled: March 6, 2013Date of Patent: August 29, 2017Assignee: Vanderbilt UniversityInventors: Roger D. Cone, Julien A. Sebag, Jacques Pantel, Savannah Y. Williams, David C. Weaver, Gary A. Sulikowski, Craig W. Lindsley, Padma S. Portonova, Chao Zhang
-
Publication number: 20150018371Abstract: Positive allosteric modulators of melanocortin receptors, especially allosteric potentiators of the receptors MC3R and MC4R are described herein. Also provided are pharmaceutical compositions containing the positive allosteric modulators and methods of treating obesity or an obesity-related disorder such as type 2 diabetes, comprising administering an effective amount of the positive allosteric modulator.Type: ApplicationFiled: March 6, 2013Publication date: January 15, 2015Inventors: Roger D. Cone, Julien A. Sebag, Jacques Pantel, Savannah Y. Williams, David C. Weaver, Gary A. Sulikowski, Craig W. Lindsley, Padma S. Portonova, Chao Zhang
-
Publication number: 20030113263Abstract: The present invention provides recombinant expression constructs comprising nucleic acid encoding mammalian melanocortin receptors, in particular MC-4 melanocortin receptor, and mammalian cells into which said recombinant expression constructs have been introduced that express functional mammalian MC-4 melanocortin receptors. The invention particularly provides such genetically engineered cells expressing the human MC4-R melanocortin receptor for screening compounds for receptor agonist and antagonist activity. The invention also provides screening methods using genetically engineered cells expressing the human MC-4 melanocortin receptor to specifically detect and identify agonists and antagonists for this melanocortin receptor. Such screening methods are provided identifying compounds with MC-4 melanocortin receptor antagonist activity having the capacity to influence or modify metabolism and feeding behavior, particularly pathological feeding behavior such as illness-induced cachexia.Type: ApplicationFiled: February 13, 2002Publication date: June 19, 2003Applicant: Oregon Health and Sciences University, a non-profit organizationInventors: Daniel L. Marks, Roger D. Cone
-
Publication number: 20030105024Abstract: The present invention provides recombinant expression constructs comprising nucleic acid encoding mammalian melanocortin receptors, and mammalian cells into which said recombinant expression constructs have been introduced that express functional mammalian melanocortin receptors. The invention provides a panel of such transformed mammalian cells expressing melanocortin receptors for screening compounds for receptor agonist and antagonist activity. The invention also provides methods for using such panels of melanocortin receptor-expressing mammalian cells to specifically detect and identify agonists and antagonists for each melanocortin receptor, as well as patterns of agonist and antagonist activity of said compounds for the class of melanocortin receptors. Such screening methods provide a means for identifying compounds with patterns of melanocortin agonist and antagonist activity which is associated with the capacity to influence or modify metabolism and behavior, particularly feeding behavior.Type: ApplicationFiled: November 5, 2002Publication date: June 5, 2003Inventors: Roger D. Cone, Wei Fan, Bruce A. Boston, Robert A. Kesterton, Dongsi Lu, Wenbiao Chen
-
Publication number: 20030044973Abstract: The present invention relates to a mammalian adrenocorticotropic hormone receptor. The invention is directed toward the isolation, characterization and pharmacological use of mammalian adrenocorticotropic hormone receptor, the gene corresponding to this receptor, a recombinant eukaryotic expression construct capable of expressing a mammalian adrenocorticotropic hormone receptor in cultures of transformed eukaryotic cells and such cultures of transformed eukaryotic cells that synthesize mammalian adrenocorticotropic hormone receptor. The invention also provides for screening ACTHR agonists and antagonists in vitro using preparations of receptor from such cultures of eukaryotic cells transformed with a recombinant eukaryotic expression construct comprising the ACTHR receptor gene. The invention specifically provides human and bovine ACTHR genes.Type: ApplicationFiled: May 20, 2002Publication date: March 6, 2003Applicant: State of OregonInventors: Roger D. Cone, Kathleen G. Mountjoy
-
Patent number: 6476187Abstract: The present invention provides recombinant expression constructs comprising nucleic acid encoding mammalian melanocortin receptors, and mammalian cells into which said recombinant expression constructs have been introduced that express functional mammalian melanocortin receptors. The invention provides a panel of such transformed mammalian cells expressing melanocortin receptors for screening compounds for receptor agonist and antagonist activity. The invention also provides methods for using such panels of melanocortin receptor-expressing mammalian cells to specifically-detect and identify agonists and antagonists for each melanocortin receptor, as well as patterns of agonist and antagonist activity of said compounds for the class of melanocortin receptors. Such screening methods provide a means for identifying compounds with patterns of melanocortin agonist and antagonist activity which is associated with the capacity to influence or modify metabolism and behavior, particularly feeding behavior.Type: GrantFiled: July 14, 1999Date of Patent: November 5, 2002Assignee: Oregon Health & Sciences UniversityInventors: Roger D. Cone, Wei Fan, Bruce A. Boston, Robert A. Kesterton, Dongsi Lu, Wenbiao Chen
-
Patent number: 6392027Abstract: The present invention relates to a mammalian adrenocorticotropic hormone receptor. The invention is directed toward the isolation, characterization and pharmacological use of mammalian adrenocorticotropic hormone receptor, the gene corresponding to this receptor, a recombinant eukaryotic expression construct capable of expressing a mammalian adrenocorticotropic hormone receptor in cultures of transformed eukaryotic cells and such cultures of transformed eukaryotic cells that synthesize mammalian adrenocorticotropic hormone receptor. The invention also provides methods for screening ACTHR agonists and antagonists in vitro using preparations of receptor from such cultures of eukaryotic cells transformed with a recombinant eukaryotic expression construct comprising the ACTHR receptor gene. The invention specifically provides human and bovine ACTHR genes.Type: GrantFiled: April 4, 2000Date of Patent: May 21, 2002Assignee: Oregon Health & Science UniversityInventors: Roger D. Cone, Kathleen G. Mountjoy
-
Patent number: 6278038Abstract: This invention provides methods and reagents for developing naturally-occurring and synthetic agonists and antagonists specific for a mammalian melanocortin receptor, and the use of such agonists and antagonists for treatment and alleviation of dysfunction and disease. The invention specifically provides reagents and methods for developing naturally-occurring and synthetic agonists and antagonists specific for a mammalian melanocortin receptor termed MC5-R. The naturally-occurring and synthetic agonists and antagonists specific for the MC5-R receptor are provided by the invention for the treatment, control, amelioration and alleviation of diseases, and dysfunctional and abnormal states related to thermoregulatory disorders, as well as other diseases relating to exocrine gland disorders, including lacrimal gland dysfunction and sebaceous gland disorders including acne and other skin problems.Type: GrantFiled: June 12, 1998Date of Patent: August 21, 2001Assignee: Oregon Health and Science UniversityInventors: Roger D. Cone, Wenbiao Chen, Malcolm J. Low
-
Patent number: 6268221Abstract: The present invention relates to a mammalian melanocyte stimulating hormone receptor (MSH-R). The invention is directed toward the isolation, characterization and pharmacological use of a mammalian melanocyte stimulating hormone receptor, the gene corresponding to this receptor, a recombinant eukaryotic expression construct capable of expressing a mammalian melanocyte stimulating hormone receptor in cultures of transformed eukaryotic cells and such cultures of transformed eukaryotic cells that synthesize mammalian melanocyte stimulating hormone receptor. The invention also provide methods for screening MSH-R agonists and antagonists in vitro using preparations of receptor from such cultures of eukaryotic cells transformed with a recombinant eukaryotic expression construct comprising the MSH-R receptor gene. The invention specifically provides human and mouse MSH-R genes.Type: GrantFiled: December 1, 1998Date of Patent: July 31, 2001Assignee: Oregon Health & Science UniversityInventors: Roger D. Cone, Kathleen G. Mountjoy
-
Patent number: 6261838Abstract: The present invention relates to a mammalian melanocortin receptor. The invention is directed toward the isolation, characterization and pharmacological use of a mammalian melanocortin receptor (MC3-R). The invention specifically provides a particular melanocortin receptor, termed MC3-R, isolated as a complementary DNA copy of mRNA corresponding to the gene for this receptor in rats. Also provided is a eukaryotic recombinant expression construct capable of expressing a mammalian melanocortin receptor in cultures of transformed eukaryotic cells and such cultures of transformed eukaryotic cells that synthesize a mammalian melanocortin receptor. The invention also provides methods for screening in vitro agonists and antagonists of such a melanocortin receptor using preparations of receptor protein from such cultures of eukaryotic cells transformed with a recombinant expression construct.Type: GrantFiled: November 13, 1998Date of Patent: July 17, 2001Assignee: Oregon Health Science UniversityInventors: Roger D. Cone, Linda Roselli-Rehfuss, Kathleen G. Mountjoy, Linda S. Robbins
-
Patent number: 6100048Abstract: The present invention provides recombinant expression constructs comprising nucleic acid encoding mammalian melanocortin receptors, and mammalian cells into which said recombinant expression constructs have been introduced that express functional mammalian melanocortin receptors. The invention provides a panel of such transformed mammalian cells expressing melanocortin receptors for screening compounds for receptor agonist and antagonist activity. The invention also provides methods for using such panels of melanocortin receptor-expressing mammalian cells to specifically detect and identify agonists and antagonists for each melanocortin receptor, as well as patterns of agonist and antagonist activity of said compounds for the class of melanocortin receptors. Such screening methods provide a means for identifying compounds with patterns of melanocortin agonist and antagonist activity which are associated with the capacity to influence or modify metabolism and behavior, particularly feeding behavior.Type: GrantFiled: September 4, 1996Date of Patent: August 8, 2000Assignee: Oregon Health Sciences UniversityInventors: Roger D. Cone, Wei Fan, Bruce A. Boston, Robert A. Kesterton, Dongsi Lu, Wenbiao Chen
-
Patent number: 6046011Abstract: The present invention relates to a mammalian adrenocorticotropic hormone receptor. The invention is directed toward the isolation, characterization and pharmacological use of mammalian adreocorticotropic hormone receptor, the gene corresponding to this receptor, a recombinant eukaryotic expression construct capable of expressing a mammalian adrenocorticotropic hormone receptor in cultures of transformed eukaryotic cells and such cultures of transformed eukaryotic cells that synthesize mammalian adrenocorticotropic hormone receptor. The invention also provides methods for screening ACTH-R agonists and antagonists in vitro using prerations of receptor from such cultures of eukaryotic cells transformed with a recombinant eukaryotic expression construct comprising the ACTH-R receptor gene. The invention specifically provides human and bovine ACTH-R genes.Type: GrantFiled: June 26, 1998Date of Patent: April 4, 2000Assignee: Oregon Health Sciences UniversityInventors: Roger D. Cone, Kathleen G. Mountjoy
-
Patent number: 5994087Abstract: The present invention relates to a mammalian melanocortin receptor. The invention is directed toward the isolation, characterization and pharmacological use of a mammalian melanocortin receptor (MC3-R). The invention specifically provides a particular melanocortin receptor, termed MC3-R, isolated as a complementary DNA copy of mRNA corresponding to the gene for this receptor in rats. Also provided is a eukaryotic recombinant expression construct capable of expressing a mammalian melanocortin receptor in cultures of transformed eukaryotic cells and such cultures of transformed eukaryotic cells that synthesize a mammalian melanocortin receptor. The invention also provides methods for screening in vitro agonists and antagonists of such a melanocortin receptor using preparations of receptor protein from such cultures of eukaryotic cells transformed with a recombinant expression construct.Type: GrantFiled: June 7, 1995Date of Patent: November 30, 1999Assignee: Oregon Health Sciences UniversityInventors: Roger D. Cone, Linda Roselli-Rehfuss, Kathleen G. Mountjoy, Linda S. Robbins
-
Patent number: 5849871Abstract: The present invention relates to a mammalian alpha-melanocyte stimulating hormone receptor. The invention is directed toward the isolation, characterization and pharmacological use of mammalian melanocyte stimulating hormone receptor, the gene corresponding to this receptor, a recombinant eukaryotic expression construct capable of expressing a mammalian melanocyte stimulating hormone receptor in cultures of transformed eukaryotic cells and such cultures of transformed eukaryotic cells that synthesize mammalian melanocyte stimulating hormone receptor. The invention also provides methods for screening MSH-R agonists and antagonists in vitro using preparations of receptor from such cultures of eukaryotic cells transformed with a recombinant eukaryotic expression construct comprising the MSH-R receptor gene. The invention specifically provides human and mouse MSH-R genes.Type: GrantFiled: June 6, 1995Date of Patent: December 15, 1998Assignee: Oregon Health Sciences UniversityInventors: Roger D. Cone, Kathleen G. Mountjoy
-
Patent number: 5837521Abstract: The present invention relates to a mammalian melanocortin receptor. The invention is directed toward the isolation, characterization and pharmacological use of a mammalian melanocortin receptor (MC3-R). The invention specifically provides a particular melanocortin receptor, termed MC3-R, isolated as a complementary DNA copy of mRNA corresponding to the gene for this receptor in rats. Also provided is a eukaryotic recombinant expression construct capable of expressing a mammalian melanocortin receptor in cultures of transformed eukaryotic cells and such cultures of transformed eukaryotic cells that synthesize a mammalian melanocortin receptor. The invention also provides methods for screening in vitro agonists and antagonists of such a melanocortin receptor using preparations of receptor protein from such cultures of eukaryotic cells transformed with a recombinant expression construct.Type: GrantFiled: April 8, 1993Date of Patent: November 17, 1998Assignee: State of OregonInventors: Roger D. Cone, Linda Roselli-Rehfuss, Kathleen G. Mountjoy, Linda S. Robbins
-
Patent number: 5773229Abstract: The present invention relates to a mammalian adrenocorticotropic hormone receptor. The invention is directed toward the isolation, characterization and pharmacological use of mammalian adrenocorticotropic hormone receptor, the gene corresponding to this receptor, a recombinant eukaryotic expression construct capable of expressing a mammalian adrenocorticotropic hormone receptor in cultures of transformed eukaryotic cells and such cultures of transformed eukaryotic cells that synthesize mammalian adrenocorticotropic hormone receptor. The invention also provides methods for screening ACTH.sup.R agonists and antagonists in vitro using preparations of receptor from such cultures of eukaryotic cells transformed with a recombinant eukaryotic expression construct comprising the ACTH.sup.R receptor gene. The invention specifically provides human and bovine ACTH.sup.R genes.Type: GrantFiled: June 7, 1995Date of Patent: June 30, 1998Assignee: State of OregonInventors: Roger D. Cone, Kathleen G. Mountjoy
-
Patent number: 5744348Abstract: A protein having the biological activity of a mammalian TSH receptor, and purified nucleic acid encoding such a protein.Type: GrantFiled: June 2, 1995Date of Patent: April 28, 1998Assignee: New England Medical Center Hospitals, Inc.Inventor: Roger D. Cone
-
Patent number: 5554729Abstract: The present invention relates to a mammalian adrenocorticotropic hormone receptor. The invention is directed toward the isolation, characterization and pharmacological use of mammalian adrenocorticotropic hormone receptor, the gene corresponding to this receptor, a recombinant eukaryotic expression construct capable of expressing a mammalian adrenocorticotropic hormone receptor in cultures of transformed eukaryotic cells and such cultures of transformed eukaryotic cells that synthesize mammalian adrenocorticotropic hormone receptor. The invention also provides methods for screening ACTH.sup.R agonists and antagonists in vitro using preparations of receptor from such cultures of eukaryotic cells transformed with a recombinant eukaryotic expression construct comprising the ACTH.sup.R receptor gene. The invention specifically provides human and bovine ACTH.sup.R genes.Type: GrantFiled: June 15, 1993Date of Patent: September 10, 1996Assignee: State of Oregon, Acting by and Through the Oregon State Board of Higher Education on Behalf of the Oregon Health Sciences UniversityInventors: Roger D. Cone, Kathleen G. Mountjoy